Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
BIOD's Cash to Debt is ranked higher than
81% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. BIOD: No Debt )
BIOD' s 10-Year Cash to Debt Range
Min: 34.94   Max: No Debt
Current: No Debt

Interest Coverage No Debt
BIOD's Interest Coverage is ranked higher than
75% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIOD: No Debt )
BIOD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -4.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -59.38
BIOD's ROE (%) is ranked higher than
59% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. BIOD: -59.38 )
BIOD' s 10-Year ROE (%) Range
Min: -517.28   Max: -28.57
Current: -59.38

-517.28
-28.57
ROA (%) -46.99
BIOD's ROA (%) is ranked higher than
61% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. BIOD: -46.99 )
BIOD' s 10-Year ROA (%) Range
Min: -283.1   Max: -25.52
Current: -46.99

-283.1
-25.52
ROC (Joel Greenblatt) (%) -1997.38
BIOD's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. BIOD: -1997.38 )
BIOD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1997.38   Max: -484.98
Current: -1997.38

-1997.38
-484.98
EBITDA Growth (%) -42.30
BIOD's EBITDA Growth (%) is ranked higher than
55% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. BIOD: -42.30 )
BIOD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 51.6
Current: -42.3

0
51.6
EPS Growth (%) -42.00
BIOD's EPS Growth (%) is ranked higher than
55% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. BIOD: -42.00 )
BIOD' s 10-Year EPS Growth (%) Range
Min: -44   Max: 113.9
Current: -42

-44
113.9
» BIOD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BIOD Guru Trades in

Q2 2013

BIOD Guru Trades in Q2 2013

Jim Simons 39,175 sh (New)
» More
Q3 2013

BIOD Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

BIOD Guru Trades in Q4 2013

Jim Simons 145,500 sh (New)
Chuck Royce 40,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with BIOD



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
BIOD's P/B is ranked higher than
88% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. BIOD: 1.90 )
BIOD' s 10-Year P/B Range
Min: 0   Max: 3.3
Current: 1.9

0
3.3
EV-to-EBIT 0.10
BIOD's EV-to-EBIT is ranked higher than
98% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. BIOD: 0.10 )
BIOD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.80
BIOD's Price/Net Cash is ranked higher than
94% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. BIOD: 1.80 )
BIOD' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 7.14
Current: 1.8

0.61
7.14
Price/Net Current Asset Value 1.80
BIOD's Price/Net Current Asset Value is ranked higher than
95% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. BIOD: 1.80 )
BIOD' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 7.14
Current: 1.8

0.61
7.14
Price/Tangible Book 1.70
BIOD's Price/Tangible Book is ranked higher than
92% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. BIOD: 1.70 )
BIOD' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 6.82
Current: 1.7

0.56
6.82
Earnings Yield (Greenblatt) 1865.00
BIOD's Earnings Yield (Greenblatt) is ranked higher than
99% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. BIOD: 1865.00 )
BIOD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 5045.8
Current: 1865

0
5045.8
Forward Rate of Return (Yacktman) -150.15
BIOD's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. BIOD: -150.15 )
BIOD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -150.15

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BDQN.Germany
Biodel, Inc., was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. Biodel is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that might be safer, more effective and more convenient for patients. The Company develops its product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Its most advanced program involves developing proprietary formulations of injectable recombinant human insulin, or RHI, designed to be more rapid-acting than the 'rapid-acting' mealtime insulin analogs currently used to treat patients with Type 1 and Type 2 diabetes. The Company, therefore, refers to these formulations as its 'ultra-rapid-acting' insulin formulations. In addition to the RHI-based formulations, the Company is using its formulation technologies to develop new ultra-rapid-acting formulations of insulin analogs. In addition to its ultra-rapid-acting insulin formulation program, the Company is developing a liquid glucagon formulation for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide